0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Food and Drug Administration |

Pulmonary Hypertension

Lester M. Crawford, Jr, DVM, PhD
JAMA. 2002;288(1):36. doi:10.1001/jama.288.1.36-JFD20007-3-1.
Text Size: A A A
Published online

Extract

The FDA has approved treprostinil sodium injection (Remodulin, United Therapeutics Corp, Research Triangle Park, NC) as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association (NYHA) Class II-IV symptoms to diminish symptoms associated with exercise.

The product was approved on the basis of two 12-week, multicenter, randomized, double-blind studies that compared treprostinil with placebo in 470 patients with NYHA Class II-IV PAH. Treprostinil was administered as a subcutaneous infusion using a portable pump, and the dose averaged 9.3 ng/kg per minute at week 12. The effect of the drug on the 6-minute walking distance, the primary end point of the studies, did not achieve statistical significance. Compared with placebo, however, treprostinil improved associated subjective measurements of shortness of breath during the 6-minute walk test called the Borg dyspnea score, and had a significant effect on a symptom assessment that combined walking distance with the Borg dyspnea score. Treprostinil also consistently improved measures of dyspnea and fatigue and signs and symptoms of AH.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
CME Related by Topic
PubMed Articles
Jobs
brightcove.createExperiences();